Min Zhang, PhDResearch Assistant Professor, Pharmaceutical Sciences
Dr. Min Zhang is a Research Assistant Professor in the Department of Pharmaceutical Sciences and a member of the Center for Pharmacogenetics, University of Pittsburgh School of Pharmacy. She received her Ph.D. in bioinformatics from Harbin Medical University in 2009. She first went to the National Center for Toxicological Research of FDA for her postdoctoral training in computational toxicology. She later joined MD Anderson Cancer Center to continue her postdoctoral training in cancer immunotherapy and precision medicine. In 2017, Dr. Zhang joined the University of Pittsburgh as a Research Assistant Professor.
Dr. Zhang has extensive background in bioinformatics, computational toxicology, and cancer pharmacogenomics. Her research activities have focused upon using computational studies to identify biomarkers for cancer precision medicine and drug induced adverse effects. Dr. Zhang’s early study focused on developing algorithms to evaluate the reproducibility and reliability of discoveries from high dimensional genomics data (Bioinformatics, 2008 & Bioinformatics, 2009). As a postdoctoral fellow in the National Center for Toxicological Research of FDA, Dr. Zhang successfully built machine learning models to predict drug induced liver injury in humans using the drug treated transcriptomic data in preclinical animal models (Chemical Research in Toxicology, 2012). She later joined MD Anderson Cancer Center for training in cancer immunotherapy and precision medicine (Lancet Oncology, 2014). Since Dr. Zhang joined the University of Pittsburgh in 2017 as a Research Assistant Professor, she has successfully led multiple cancer pharmacogenomics projects as senior authors (Nature Communications. 2018; Theranostics. 2020.). Dr. Zhang’s current research interests focus on developing computational tools to integrate multi-dimensional genomic, epigenetic, and clinical data from large-scale cancer pharmacogenomics database, such as L1000, GTEx, and TCGA databases, for precision medicine and drug induced adverse reaction studies.
Wu Z, Li S, Tang X, Wang Y, Guo W, Cao G, Chen K, Zhang M#, Guan M#, Yang D#. “Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer.” Theranostics. 2020;10(9):3939-3951. doi: 10.7150/thno.39341. (#: Co-Corresponding author)
Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M#, Yang D#. “Systematic Identification of Non-coding Pharmacogenomic Landscape in Cancer”. Nature Communications. 2018 Aug 9; 9(1):3192. doi: 10.1038/s41467-018-05495-9. (#: Co-Corresponding author)
Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W, Yang D. “lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer”. Cancer Cell. 2018 Apr 9;33(4):706-720.e9. doi: 10.1016/j.ccell.2018.03.006.33.
Zhang M, Liu G, Xue F, et al. “Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer”. Gynecologic Oncology. 2016 April, 141(1): 57–64. doi: 10.1016/j.ygyno.2016.01.004.
Westin J, Chu F, Zhang M, et al. “Safety and Activity of Programmed Death-1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Phase II Trial”. The Lancet Oncology. 2014, 15(1): 69-77.
Zhang M, Chen M, Tong W. “Is Toxicogenomics a More Reliable and Sensitive Biomarker than Conventional Indicators from Rats To Predict Drug-Induced Liver Injury in Humans”. Chemical Research in Toxicology. 2012, 25(1): 122-129.
MAQC Consortium (including Zhang M). “The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models”. Nature Biotechnology. 2010, 28(8): 827-838.
Zhang M, Zhang L, Zou J, et al. “Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes”. Bioinformatics. 2009, 25(13): 1662-1668.
Zhang M, Yao C, Guo Z, et al. “Apparently low reproducibility of true differential expression discoveries in microarray studies”. Bioinformatics. 2008, 24(18): 2057-2063.
Xi Y, Li Y, Xu P, Li S, Liu Z, Tung H, Cai X, Wang J, Huang H, Wang M, Xu M, Ren S, Li S, Zhang M, Lee Y, Huang L, Yang D, He J, Huang Z, Xie W. “The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1”. Sci Adv. 2021 June (Accepted).
Xu P, Xi Y, Zhu J, Zhang M, Luka Z, Stolz DB, Cai X, Xie Y, Xu M, Ren S, Huang Z, Yang D, York JD, Ma X, Xie W. “Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis.” Gastroenterology. 2021 Apr 2:S0016-5085(21)00575-8. doi: 10.1053/j.gastro.2021.03.048.
Guo W, Wang Y, Yang M, Wang Z, Wang Y, Chaurasia S, Wu Z, Zhang M, Yadav GS, Rathod S, Concha-Benavente F, Fernandez C, Li S, Xie W, Ferris RL, Kammula US, Lu B, Yang D. “LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.” Sci Adv. 2021 Feb 10;7(7):eabb3555. doi: 10.1126/sciadv.abb3555.
Wang Y, Zhang M, Wang Z, Guo W, Yang D. “MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.” Mol Carcinog. 2020 Oct;59(10):1188-1198. doi: 10.1002/mc.23248.
Xiong X, Rao G, Roy RV, Zhang Y, Means N, Dey A, Tsaliki M, Saha S, Bhattacharyya S, Dhar Dwivedi SK, Rao CV, McCormick DJ, Dhanasekaran D, Ding K, Gillies E, Zhang M, Yang D, Bhattacharya R, Mukherjee P. “Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.” FASEB J. 2020 Sep;34(9):12024-12039. doi: 10.1096/fj.201902826RR.
Dwivedi SKD, Rao G, Dey A, Buechel M, Zhang Y, Zhang M, Yang D, Mukherjee P, Bhattacharya R. “Targeting the TGFβ pathway in uterine carcinosarcoma.” Cell Stress. 2020 Aug 25;4(11):252-260. doi: 10.15698/cst2020.11.234.
Gao L, Li B, Wang J, Shen D, Yang M, Sun R, Tung HC, Xu M, Ren S, Zhang M, Yang D, Lu B, Wang H, Liu Y, Xie W. “Activation of Liver X Receptor α Sensitizes Mice to T-Cell Mediated Hepatitis.” Hepatol Commun. 2020 Aug 12;4(11):1664-1679. doi: 10.1002/hep4.1584.
Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. “IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.” Cancer Letters. 2020 May 01; 477: 19-30. doi: 10.1016/j.canlet.2020.02.036.
Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. “Data analysis of PD-1 antibody in the treatment of melanoma patients.” Data in Brief. 2020 June; doi: 10.1016/j.dib.2020.105523.
Zhang M, Yang D, Gold B. “Origin of mutations in genes associated with human glioblastoma multiform cancer: random polymerase errors versus deamination.” Heliyon. 2019 Mar 7;5(3):e01265. doi: 10.1016/j.heliyon.2019.e01265.
Chakraborty PK, Murphy B, Mustafi SB, Dey A, Xiong 11X, Rao G, Naz S, Zhang M, et al. “Cystathionine β-synthase regulates mitochondrial morphogenesis in ovarian cancer”. FASEB Journal. 2018 Aug;32(8):4145-4157. doi: 10.1096/fj.201701095R.
McKenzie JA, Mbofung RM, Malu S, Zhang M, et al. “The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy”. JNCI: Journal of the National Cancer Institute. 2018 Jul 1;110(7):777-786. doi: 10.1093/jnci/djx257.
Zhang M, Yang D, Gold B. “The Adenomatous Polyposis Coli (APC) mutation spectra in different anatomical regions of the large intestine in colorectal cancer”. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2018 May 1; 810:1-5. doi: 10.1016/j.mrfmmm.2018.04.003.
Mbofung RM, McKenzie JA, Malu S, Zhang M, et al. “HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes”. Nature Communications. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z.
Yang D, Zhang M, Gold B. “Origin of Somatic Mutations in β-Catenin versus Adenomatous Polyposis Coli in Colon Cancer: Random Mutagenesis in Animal Models versus Nonrandom Mutagenesis in Humans”. Chemical Research in Toxicology. 2017 Jul 17;30(7):1369-1375. doi: 10.1021/acs.chemrestox.7b00092.
Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, et al. “Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia”. Oncotarget. 2017 Jul 6;8(48):83354-83369. doi: 10.18632/oncotarget.19042.
Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, et al. “MICU1 drives glycolysis and chemoresistance in ovarian cancer”. Nature Communications. 2017 May 22;8:14634. doi: 10.1038/ncomms14634.
Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Hacken E, Jäger U, Vanura K, O’Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, et al. “Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition”. Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9.
23. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature communications. 2016, Apr 4;7:11169. doi: 10.1038/ncomms11169.
Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, et al. “Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance”. Blood. 2014, 123(17): 2691-702.
Rawal S, Chu F, Zhang M, et al. “Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment”. The Journal of Immunology. 2013, 190(12): 6681-6693.
Kojima K, Kornblau S, Ruvolo Vivian, Dilip A, Duvvuri S, Davis, R, Zhang M, et al. “Prognostic impact and targeting of CRM1 in acute myeloid leukemia”. Blood. 2013, 121(20): 4166-4174.
Chen M, Zhang M, Borlak J, Tong W. “A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science”. Toxicological Sciences. 2012, 130(2): 217-228.
Ding Y, Chen M, Liu Z, Ding D, Ye Y, Zhang M, et al. “atBioNet–an Integrated Network Analysis Tool for Genomics and Biomarker Discovery”. BMC Genomics. 2012, DOI: 10.1186/1471-2164-13-325.
Khalili J, Liu S, Rodriguez-Cruz T, Whittington M, Wardell S, Liu C, Zhang M, Cooper Z, Frederick D, Li Y, Zhang M, et al. “Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression via Induction of Interleukin-1 in Melanoma”. Clinical Cancer Research. 2012,18(19): 5329-5340.
Gu Y, Yang D, Zou J, Ma W, Wu R, Zhao W, Zhang Y, Xiao H, Gong X, Zhang M, et al. “Systematic interpretation of comutated genes in large-scale mutation profile”. Molecular Cancer Therapeutics. 2010, 9(8): 2186-2195.
Zhu J, Xiao H, Shen X, Wang J, Zou J, Zhang L, Yang D, Ma W, Yao C, Gong X, Zhang M, et al. “Viewing cancer genes from co-evolving gene modules”. Bioinformatics. 2010, 26(7): 919-924.
Wang D, Wang C, Zhang L, Xiao H, Shen X, Ren L, Zhao W, Hong G, Zhang Y, Zhu J, Zhang M, et al. “Evaluation of cDNA Microarray Data by Multiple Clones Mapping to the Same Transcript”. OMICS: A Journal of Integrative Biology. 2009, 13(6): 493-499.
Yang D, Li Y, Xiao H, Guo Z, Liu Q, Zhang M, et al. “Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories”. Bioinformatics. 2008, 24(2): 265-271.
Guo Z, Li Y, Gong X, Yao C, Ma W, Wang D, Li Y, Zhu J, Zhang M, et al. “Edge-based scoring and searching method for identifying condition-responsive protein-protein interaction subnetwork”. Bioinformatics. 2007, 23(16): 2121-2128.
Zhu J, Wang J, Guo Z, Zhang M, et al. “GO-2D: identifying 2-dimensional cellularlocalized functional modules in Gene Ontology”. BMC Genomics. 2007, 8:30 DOI: 10.1186/1471-2164-8-30.
Xu J, Guo Z, Zhang M, et al. “Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules”. Molecular Medicine. 2006, 12(1-3): 25-33.